These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 31251100)
21. Progress in high-sensitivity hybrid LC-MS/MS methods for the bioanalysis of protein drugs and performance tests for their validation. Duggan JX Bioanalysis; 2018 Jul; 10(13):983-986. PubMed ID: 29993264 [No Abstract] [Full Text] [Related]
22. Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: practical considerations in assay development and validation. Liu G; Ji QC; Dodge R; Sun H; Shuster D; Zhao Q; Arnold M J Chromatogr A; 2013 Apr; 1284():155-62. PubMed ID: 23466204 [TBL] [Abstract][Full Text] [Related]
23. Experimental design for the optimization and robustness testing of a liquid chromatography tandem mass spectrometry method for the trace analysis of the potentially genotoxic 1,3-diisopropylurea. Székely G; Henriques B; Gil M; Alvarez C Drug Test Anal; 2014 Sep; 6(9):898-908. PubMed ID: 24243602 [TBL] [Abstract][Full Text] [Related]
24. Evaluation, identification and impact assessment of abnormal internal standard response variability in regulated LC-MS bioanalysis. Fu Y; Barkley D; Li W; Picard F; Flarakos J Bioanalysis; 2020 Apr; 12(8):545-559. PubMed ID: 32352315 [TBL] [Abstract][Full Text] [Related]
25. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. Ramanathan R; Jemal M; Ramagiri S; Xia YQ; Humpreys WG; Olah T; Korfmacher WA J Mass Spectrom; 2011 Jun; 46(6):595-601. PubMed ID: 21630388 [TBL] [Abstract][Full Text] [Related]
26. Power of Orbitrap-based LC-high resolution-MS/MS for comprehensive drug testing in urine with or without conjugate cleavage or using dried urine spots after on-spot cleavage in comparison to established LC-MS Michely JA; Meyer MR; Maurer HH Drug Test Anal; 2018 Jan; 10(1):158-163. PubMed ID: 28755512 [TBL] [Abstract][Full Text] [Related]
27. An automation-assisted generic approach for biological sample preparation and LC-MS/MS method validation. Zhang J; Wei S; Ayres DW; Smith HT; Tse FL Bioanalysis; 2011 Sep; 3(17):1975-86. PubMed ID: 21899506 [TBL] [Abstract][Full Text] [Related]
29. High-resolution MS in regulated bioanalysis: where are we now and where do we go from here? Fung EN; Jemal M; Aubry AF Bioanalysis; 2013 May; 5(10):1277-84. PubMed ID: 23721448 [TBL] [Abstract][Full Text] [Related]
30. Use of high-pH (basic/alkaline) mobile phases for LC-MS or LC-MS/MS bioanalysis. Tan A; Fanaras JC Biomed Chromatogr; 2019 Jan; 33(1):e4409. PubMed ID: 30315658 [TBL] [Abstract][Full Text] [Related]
31. Highly reproducible improved label-free quantitative analysis of cellular phosphoproteome by optimization of LC-MS/MS gradient and analytical column construction. Ahsan N; Belmont J; Chen Z; Clifton JG; Salomon AR J Proteomics; 2017 Aug; 165():69-74. PubMed ID: 28634120 [TBL] [Abstract][Full Text] [Related]
32. Development and analytical comparison of microflow and nanoflow liquid chromatography/mass spectrometry procedures for quantification of cardiac troponin T in mouse hearts. Olkowicz M; Rybakowska I; Chlopicki S; Smolenski RT Talanta; 2015 Jan; 131():510-20. PubMed ID: 25281134 [TBL] [Abstract][Full Text] [Related]
33. Discovery, identification and mitigation of isobaric sulfate metabolite interference to a phosphate prodrug in LC-MS/MS bioanalysis: Critical role of method development in ensuring assay quality. Yuan L; Ji QC J Pharm Biomed Anal; 2018 Jun; 155():141-147. PubMed ID: 29631074 [TBL] [Abstract][Full Text] [Related]
34. Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC-MS/MS. Faria M; Halquist MS; Yuan M; Mylott W; Jenkins RG; Karnes HT J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1001():156-68. PubMed ID: 26279007 [TBL] [Abstract][Full Text] [Related]
35. A convenient strategy to overcome interference in LC-MS/MS analysis: Application in a microdose absolute bioavailability study. Yuan L; Huang C; Liu-Kreyche P; Voronin K; Fancher RM; Allentoff A; Zheng N; Iyer R; Zhu L; Pillutla R; Ji QC J Pharm Biomed Anal; 2019 Feb; 165():198-206. PubMed ID: 30553110 [TBL] [Abstract][Full Text] [Related]
36. Very complex internal standard response variation in LC-MS/MS bioanalysis: root cause analysis and impact assessment. van de Merbel NC; Koster RA; Ohnmacht C Bioanalysis; 2019 Sep; 11(18):1693-1700. PubMed ID: 31566440 [TBL] [Abstract][Full Text] [Related]
37. Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay. Iwamoto N; Takanashi M; Shimada T; Sasaki J; Hamada A AAPS J; 2019 Aug; 21(6):101. PubMed ID: 31432293 [TBL] [Abstract][Full Text] [Related]
38. Recent development in high-throughput bioanalytical support for in vitro ADMET profiling. Shou WZ; Zhang J Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):321-36. PubMed ID: 20163321 [TBL] [Abstract][Full Text] [Related]
39. Validation challenges in liquid chromatography-tandem mass spectrometry methods for the analysis of naturally occurring compounds in foodstuffs. Golubović J; Heath E; Heath D Food Chem; 2019 Oct; 294():46-55. PubMed ID: 31126488 [TBL] [Abstract][Full Text] [Related]
40. A novel LC-MS approach for the detection of metabolites in DMPK studies. Plumb RS; Mather J; Little D; Rainville PD; Twohig M; Harland G; Kenny DJ; Nicholson JK; Wilson ID; Kass IJ Bioanalysis; 2010 Oct; 2(10):1767-78. PubMed ID: 21083328 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]